Cambridge-based Owlstone Medical, which provides disease breathalysers, has appointed Neil Tween as chief financial officer.

Tween was previously vice-president and group financial controller at GW Pharmaceuticals, which grew from a medium-sized UK-listed partner-funded R&D company to a 900-headcount global commercial organisation and where he was involved in more than $1 billion of public markets fundraising.

Prior to that he was financial Controller at Jagex, and spent six years with Deloitte, advising a range of listed and private biotech and pharmaceutical clients. Tween is a chartered accountant.

Billy Boyle, co-founder and chief executive at Owlstone Medical, said: “Neil is an excellent addition to the world-class team we have built at Owlstone Medical to realise the potential of Breath Biopsy [the company’s product] in a wide range of applications including oncology and liver disease. He brings the experience and financial discipline that will see us through this important next phase of growth, and I and the board welcome him to the team.”

Tween said: “I am delighted to be joining Owlstone Medical at this exciting time and look forward to contributing to the growth of the business as it pursues its important mission to save over 100,000 lives and $1.5 billion in healthcare costs.”